BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), an organization dedicated to bettering affected person outcomes via diagnostics, radiotherapeutics and synthetic intelligence options that allow clinicians to Find, Fight and Follow illness, introduced PYLARIFY AI information can be offered on the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which can be held September 9-13, 2023 in Vienna, Austria.
PYLARIFY AI™ (aPROMISE) is the one deep studying enabled FDA-cleared medical gadget software program to supply standardized PSMA PET reporting on PSMA PET/CT photographs, together with these achieved utilizing PYLARIFY® (piflufolastat F18) PET/CT.1 Standardized PSMA PET reporting gives constant and exact illness burden quantification in help of affected person administration and monitoring over time.2,3,4
“With the increased availability of PSMA scanning for disease monitoring, the recognition and demand for better standardization and quantitative reports for PSMA PET has significantly heightened,” stated Etienne Montagut, Chief Business Officer, Lantheus. “We are thrilled to have Dr. Duriseti present the latest development for our PSMA AI platform, which allows consistent and accurate reporting of change in disease burden in total body PSMA PET/CT. By harnessing our deep learning algorithm and extensive PSMA datasets, we are committed to sustaining our efforts to improve guidance for prostate cancer patient diagnosis and treatment.”
Top Rated Oral Presentation particulars are as follows:
Date & Time: Sunday, September 10, 2023, 8:00 am – 9:30 am CET
Session Number: 206
Session Title: Clinical Oncology Track – TROP Session: Prostate Cancer Staging
Title: Updated Automated PROMISE evaluation: Treatment response analysis strategy on metastatic prostate most cancers sufferers based mostly on PSMA PET/CT
Presenter: Sai Duriseti, Assistant Professor, University of California, Department of Radiation Oncology, Los Angeles, USA.
Poster Number: OP-041
About Lantheus
With greater than 65 years of expertise in delivering life-changing science, Lantheus is dedicated to bettering affected person outcomes via diagnostics, radiotherapeutics and synthetic intelligence options that allow clinicians to Find, Fight and Follow illness. Lantheus is headquartered in Massachusetts and has places of work in New Jersey, Canada and Sweden. For extra data, go to www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press launch comprises “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995, as amended, which might be topic to dangers and uncertainties and are made pursuant to the secure harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements could also be recognized by their use of phrases corresponding to “committed,” “will,” “potential” and different related phrases. Such forward-looking statements are based mostly upon present plans, estimates and expectations which might be topic to dangers and uncertainties that would trigger precise outcomes to materially differ from these described within the forward-looking statements. The inclusion of forward-looking statements shouldn’t be thought to be a illustration that such plans, estimates and expectations can be achieved. Readers are cautioned to not place undue reliance on the forward-looking statements contained herein, which converse solely as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking assertion, whether or not because of new data, future developments or in any other case, besides as could also be required by regulation. Risks and uncertainties that would trigger our precise outcomes to materially differ from these described within the forward-looking statements embrace (i) our potential to efficiently launch PYLARIFY AI as a business product; (ii) the market receptivity to PYLARIFY AI as a brand new digital utility for quantitative evaluation of PSMA PET/CT photographs in prostate most cancers; (iii) the mental property safety of PYLARIFY AI; (iv) interruptions or efficiency issues related to our digital utility, together with a service outage; (v) a community or information safety incident that permits unauthorized access to our community or information or our prospects’ information; and (vi) the dangers and uncertainties mentioned in our filings with the Securities and Exchange Commission (together with these described within the Risk Factors part in our Annual Reports on Form 10-Okay and our Quarterly Reports on Form 10-Q).
1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K211655
2https://pubmed.ncbi.nlm.nih.gov/34463809/
3https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220590
4https://jnm.snmjournals.org/content/63/supplement_2/2496
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
[email protected]
